Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04648475 | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04649983 | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 |
| clinicaltrials |
| NCT05697510 | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM(SILTUXILAM) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05503355 | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML | unknown | Phase 1 / Phase 2 | 80 | BioSight Ltd.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05448599 | A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | unknown | Phase 1 / Phase 2 | 120 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05429905 | Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia | unknown | Phase 1 / Phase 2 | 48 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05740917 | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS | unknown | Phase 1 | 82 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 18 | Telios Pharma, Inc.INDUSTRY | 8 | Feb 17, 2023 | clinicaltrials |
| NCT05727683 | CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 33 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05381662 | CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment | unknown | Phase 1 / Phase 2 | 10 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05210907 | Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia | unknown | Phase 1 | 5 | Seoul National University HospitalOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05381181 | Safety and Efficacy Evaluation of Next-generation CD19-UCART | unknown | Phase 1 | 20 | Bioray LaboratoriesINDUSTRY | 0 | Jan 27, 2023 | clinicaltrials |
| NCT05679687 | ThisCART19A Bridging to alloHSCT for R/R B-ALL | unknown | Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04100187 | Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia | unknown | Phase 1 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 1, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05596266 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Xuanwu Hospital, BeijingOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04684472 | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | unknown | Phase 1 | 18 | Liqun ZouOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05528887 | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies | unknown | Phase 1 | 10 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05488132 | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05473221 | Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05467202 | Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467254 | Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05463640 | Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | unknown | Phase 1 | 15 | Beijing Boren HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05398614 | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies | unknown | Phase 1 | 18 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05379647 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT04886206 | Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation(ILDA) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT04709458 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | unknown | Phase 1 | 10 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | May 3, 2022 | clinicaltrials |
| NCT05350852 | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL | unknown | Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05333705 | Donor Immune Cell Therapy for Acute Myeloid Leukemia | unknown | Phase 1 | 15 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05309213 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 / Phase 2 | 58 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Apr 4, 2022 | clinicaltrials |
| NCT02752243 | CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. | unknown | Phase 1 / Phase 2 | 32 | Peter BaderOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05297123 | Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid | unknown | Phase 1 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
| NCT04604691 | Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) | unknown | Phase 1 | 20 | Seoul National University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | unknown | Phase 1 | 136 | Aptevo Research and Development LLCINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05223686 | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 4, 2022 | clinicaltrials |
| NCT03412292 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04187495 | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Apr 18, 2023source: clinicaltrials